Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Meeting Abstracts

New dimensions in serology

Sacha Gnjatic
Sacha Gnjatic
Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2008
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Immunization of heterologous species with cancer cells or extracts to analyze the resulting antisera for cancer-specific antibodies inaugurated the search for human tumor antigens that could be used in cancer diagnosis and therapy. Technologies for generating monoclonal antibodies revolutionized the discovery process for cell surface and intracellular antigens of human cancer cells, beginning a new era in the clinical application of antibodies. The capacity of the immune system to recognize human cancer antigens was further substantiated with the development of autologous typing−an approach in which tumor cells, lymphocytes, antibody, and control cells are all derived from the same patient, thus eliminating the contribution of alloreactivity in the observed results. This development has led to a growing list of antibody-recognized antigens that are immunogenic in the host of origin, including mutational, overexpressed, viral, and cancer-testis (CT) antigens. Antigens in the latter category, including NY-ESO-1 and MAGE-A3, have been extensively studied and shown to spontaneously elicit antibody responses in a proportion of patients that correlate with T-cell immunity.

With the sequencing of the human genome and rapid and effective protein expression systems, it is now possible to envisage screening the human proteome with the human antibody repertoire, a process we refer to as seromic analysis. To this end, human protein arrays including a subset of antigens identified in the Cancer Immunome: SEREX Database were constructed, in collaboration with ProCognia, using their novel method for attaching proteins to the glass surface. Sera previously shown by ELISA to have reactivity to selected antigens were analyzed for reactivity to the same antigens using the arrays to evaluate their sensitivity and specificity. This technology has provided us with the analytic tools necessary to identify antigens with immunogenicity in cancer patients, as well as to expand the analysis to more antigens in larger cohorts of cancer patients. Preliminary results from array-based serological analyses of NSCLC patients identified a variety of novel antigens that may have utility as targets for cancer vaccine development. These data could also contribute to the elucidation of biomarker signatures for NSCLC based on seroreactivity, and help to define immune responses that can be correlated with clinical benefit for the cancer patient.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

  • Copyright © 2008 by Sacha Gnjatic
PreviousNext
Back to top
Cancer Immunity Archive: 8 (Suppl 1)
January 2008
Volume 8, Issue Suppl 1
  • Table of Contents

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
New dimensions in serology
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
New dimensions in serology
Sacha Gnjatic
Cancer Immun January 1 2008 (8) (Suppl 1) 5;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
New dimensions in serology
Sacha Gnjatic
Cancer Immun January 1 2008 (8) (Suppl 1) 5;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • The collaboration for AIDS vaccine discovery: A model for accelerating research
  • Robust T-cell responses and clinical responses following long peptide vaccination against high risk HPV-16
  • Human monoclonal antibodies and analytic vaccinology
Show more Meeting Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement